NWBO News Thursday, June 19, 2014 5:16:09 PM $NWBO
Nasdaq stocks posting largest percentage decreases
AP - 11 mins ago
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
SHAREHOLDER ALERT: Investigation on Behalf of Northwest Biotherapeutics, Inc. Investors Announced by Law Offices of Howard G. Smith
Business Wire - 1 hr 43 mins ago
Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of Northwest Biotherapeutics, Inc. ("Northwest Biotherapeutics" or the "Company"
(NASDAQ:NWBO). The investigation concerns possible violations of federal securities laws and focuses on certain statements issued by Northwest Biotherapeutics concerning the Company's operations and prospects.
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Northwest Biotherapeutics, Inc.
PR Newswire - Thu Jun 19, 1:30PM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Northwest Biotherapeutics, Inc. ("Northwest Biotherapeutics" or the "Company" (NasdaqCM: NWBO). The investigation focuses on whether the Company and its executives violated federal securities laws.
Investor Alert: Investigation into Northwest Biotherapeutics, Inc. Announced by Holzer & Holzer, LLC
Business Wire - Thu Jun 19, 1:11PM CDT
Holzer & Holzer, LLC is investigating whether Northwest Biotherapeutics, Inc. ("Northwest Bio" or the "Company" (NASDAQ: NWBO) and/or certain of its officers complied with the federal securities laws in making public statements regarding its experimental cancer vaccine, DCVax-Direct. On June 19, 2014, TheStreet.com published a report in which Dr. Aman Buzdar is quoted as criticizing Northwest Bio for issuing a series of public statements regarding preliminary results of its ongoing DCVax-Direct clinical trial. Dr. Buzdar is the vice president of clinical research at MD Anderson, which is conducting the clinical trial. The price of Northwest Bio stock has declined significantly on the report.
EQUITY ALERT: The Rosen Law Firm Announces Investigation of Securities Fraud Claims Against Northwest Biotherapeutics, Inc. - NWBO
Business Wire - Thu Jun 19, 12:09PM CDT
The Rosen Law Firm, P.A. announces that it is investigating potential securities fraud claims against Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) resulting from allegations that the Company may have made false and misleading disclosures concerning its experimental cancer vaccine, DCVax-Direct.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Northwest Biotherapeutics, Inc. - NWBO
PR Newswire - Thu Jun 19, 10:16AM CDT
Pomerantz LLP is investigating claims on behalf of investors of Northwest Biotherapeutics, Inc. ("Northwest Biotherapeutics" or the "Company" (NASDAQ: NWBO). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237.
Prestigious Cancer Hospital Rebukes Northwest Bio for 'Inappropriate' Data Disclosures
at The Street - Thu Jun 19, 7:46AM CDT
Northwest Bio has issued five press releases and held a conference call in the past month to disclose preliminary and unconfirmed results from individual cancer patients who have had single, inoperable tumors injected repeatedly with DCVax-Direct....
World Glioblastoma Multiforme Therapeutics Market to Reach USD 583 Mln in 2019, States GBI Research in Its Report Published at MarketPublishers.com
PRWeb - Wed Jun 18, 1:03PM CDT
Owing to the poor prognosis under presently available treatment options, therapies with high potency are in strong demand in the world glioblastoma multiforme (GBM) market. In newly diagnosed patients, the present standard of care, encompassing radiation therapy, resection surgery and chemotherapy with Merck's Temodar, has a maximum overall survival (OS) of fifteen months and almost inevitable tumor recurrence. Presently available therapeutic options for recurrent GBM are carmustine, Roche's Avastin (bevacizumab) and some other chemotherapy drugs used in off-label ways. However, these therapies merely provide limited OS benefit, thus leaving high unmet need in this patient pool.
Sales, Clinical Hold Removal, Trial Initiations, and Committee Recommendations - Analyst Notes on Geron, Zalicus, Northwest Biotherapeutics, Progenics and TG Therapeutics
PR Newswire - Tue Jun 17, 4:30AM CDT
Today, Analysts Review released its analysts' notes regarding Geron Corporation (NASDAQ: GERN), Zalicus Inc. (NASDAQ: ZLCS), Northwest Biotherapeutics, Inc. (NASDAQ: NWBO), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX) and TG Therapeutics, Inc. (NASDAQ: TGTX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3775-100free.
NW BIO NAMED TO TWO RUSSELL INDEXES
PR Newswire - Mon Jun 16, 7:15AM CDT
Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it has been added to two prestigious Russell Indexes: the Russell Global and the Russell 3,000 Indexes. The preliminary announcement was made on Saturday, June 14, 2014, and becomes effective on June 27, 2014.
3 Health Care Trends That Could Smoke Marijuana's Growth Potential
Sean Williams, The Motley Fool - Motley Fool - Sun Jun 15, 9:32AM CDT
According to data released late last year from the Bureau of Labor Statistics, the health care sector is on pace to be the biggest source of jobs growth over the next decade. Based on its findings, the top three prospective job growth industries all...
This Week in Biotech: Tulipmania Ensues in the Hepatitis C Sector
Sean Williams, The Motley Fool - Motley Fool - Sat Jun 14, 10:25AM CDT
As we saw in the first part of "This Week in Biotech," it was an extremely busy week in the health-care sector. In the first part of our regular biotech review, we noted five companies directly affected by regulatory actions, either from the Food...
5 Stocks Under $10 Set to Soar Higher
at The Street - Thu Jun 12, 1:43PM CDT
These under-$10 stocks look ready to break out and trade higher from current levels.
Why Synaptics, Ulta Salon, and Northwest Biotherapeutics Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Wed Jun 11, 4:15PM CDT
We knew that a "real" down trading session was around the corner for the broad-based S&P 500 , and it finally arrived on Wednesday -- though who knew that it would come on a day when the both pieces of U.S. economic data were positive? ...
Why Northwest Biotherapeutics Inc. Shares Hit a High Note
Sean Williams, The Motley Fool - Motley Fool - Wed Jun 11, 1:09PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Northwest Biotherapeutics , or NW Bio, a...
Nasdaq stocks posting largest percentage decreases
AP - 11 mins ago
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
SHAREHOLDER ALERT: Investigation on Behalf of Northwest Biotherapeutics, Inc. Investors Announced by Law Offices of Howard G. Smith
Business Wire - 1 hr 43 mins ago
Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of Northwest Biotherapeutics, Inc. ("Northwest Biotherapeutics" or the "Company"
(NASDAQ:NWBO). The investigation concerns possible violations of federal securities laws and focuses on certain statements issued by Northwest Biotherapeutics concerning the Company's operations and prospects. Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Northwest Biotherapeutics, Inc.
PR Newswire - Thu Jun 19, 1:30PM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Northwest Biotherapeutics, Inc. ("Northwest Biotherapeutics" or the "Company"
(NasdaqCM: NWBO). The investigation focuses on whether the Company and its executives violated federal securities laws. Investor Alert: Investigation into Northwest Biotherapeutics, Inc. Announced by Holzer & Holzer, LLC
Business Wire - Thu Jun 19, 1:11PM CDT
Holzer & Holzer, LLC is investigating whether Northwest Biotherapeutics, Inc. ("Northwest Bio" or the "Company"
(NASDAQ: NWBO) and/or certain of its officers complied with the federal securities laws in making public statements regarding its experimental cancer vaccine, DCVax-Direct. On June 19, 2014, TheStreet.com published a report in which Dr. Aman Buzdar is quoted as criticizing Northwest Bio for issuing a series of public statements regarding preliminary results of its ongoing DCVax-Direct clinical trial. Dr. Buzdar is the vice president of clinical research at MD Anderson, which is conducting the clinical trial. The price of Northwest Bio stock has declined significantly on the report. EQUITY ALERT: The Rosen Law Firm Announces Investigation of Securities Fraud Claims Against Northwest Biotherapeutics, Inc. - NWBO
Business Wire - Thu Jun 19, 12:09PM CDT
The Rosen Law Firm, P.A. announces that it is investigating potential securities fraud claims against Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) resulting from allegations that the Company may have made false and misleading disclosures concerning its experimental cancer vaccine, DCVax-Direct.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Northwest Biotherapeutics, Inc. - NWBO
PR Newswire - Thu Jun 19, 10:16AM CDT
Pomerantz LLP is investigating claims on behalf of investors of Northwest Biotherapeutics, Inc. ("Northwest Biotherapeutics" or the "Company"
(NASDAQ: NWBO). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. Prestigious Cancer Hospital Rebukes Northwest Bio for 'Inappropriate' Data Disclosures
at The Street - Thu Jun 19, 7:46AM CDT
Northwest Bio has issued five press releases and held a conference call in the past month to disclose preliminary and unconfirmed results from individual cancer patients who have had single, inoperable tumors injected repeatedly with DCVax-Direct....
World Glioblastoma Multiforme Therapeutics Market to Reach USD 583 Mln in 2019, States GBI Research in Its Report Published at MarketPublishers.com
PRWeb - Wed Jun 18, 1:03PM CDT
Owing to the poor prognosis under presently available treatment options, therapies with high potency are in strong demand in the world glioblastoma multiforme (GBM) market. In newly diagnosed patients, the present standard of care, encompassing radiation therapy, resection surgery and chemotherapy with Merck's Temodar, has a maximum overall survival (OS) of fifteen months and almost inevitable tumor recurrence. Presently available therapeutic options for recurrent GBM are carmustine, Roche's Avastin (bevacizumab) and some other chemotherapy drugs used in off-label ways. However, these therapies merely provide limited OS benefit, thus leaving high unmet need in this patient pool.
Sales, Clinical Hold Removal, Trial Initiations, and Committee Recommendations - Analyst Notes on Geron, Zalicus, Northwest Biotherapeutics, Progenics and TG Therapeutics
PR Newswire - Tue Jun 17, 4:30AM CDT
Today, Analysts Review released its analysts' notes regarding Geron Corporation (NASDAQ: GERN), Zalicus Inc. (NASDAQ: ZLCS), Northwest Biotherapeutics, Inc. (NASDAQ: NWBO), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX) and TG Therapeutics, Inc. (NASDAQ: TGTX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3775-100free.
NW BIO NAMED TO TWO RUSSELL INDEXES
PR Newswire - Mon Jun 16, 7:15AM CDT
Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it has been added to two prestigious Russell Indexes: the Russell Global and the Russell 3,000 Indexes. The preliminary announcement was made on Saturday, June 14, 2014, and becomes effective on June 27, 2014.
3 Health Care Trends That Could Smoke Marijuana's Growth Potential
Sean Williams, The Motley Fool - Motley Fool - Sun Jun 15, 9:32AM CDT
According to data released late last year from the Bureau of Labor Statistics, the health care sector is on pace to be the biggest source of jobs growth over the next decade. Based on its findings, the top three prospective job growth industries all...
This Week in Biotech: Tulipmania Ensues in the Hepatitis C Sector
Sean Williams, The Motley Fool - Motley Fool - Sat Jun 14, 10:25AM CDT
As we saw in the first part of "This Week in Biotech," it was an extremely busy week in the health-care sector. In the first part of our regular biotech review, we noted five companies directly affected by regulatory actions, either from the Food...
5 Stocks Under $10 Set to Soar Higher
at The Street - Thu Jun 12, 1:43PM CDT
These under-$10 stocks look ready to break out and trade higher from current levels.
Why Synaptics, Ulta Salon, and Northwest Biotherapeutics Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Wed Jun 11, 4:15PM CDT
We knew that a "real" down trading session was around the corner for the broad-based S&P 500 , and it finally arrived on Wednesday -- though who knew that it would come on a day when the both pieces of U.S. economic data were positive? ...
Why Northwest Biotherapeutics Inc. Shares Hit a High Note
Sean Williams, The Motley Fool - Motley Fool - Wed Jun 11, 1:09PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Northwest Biotherapeutics , or NW Bio, a...
